

Datasheet: HCA331 BATCH NUMBER 164793

HUMAN ANTI IPILIMUMAB (DRUG/TARGET COMPLEX)		
IPILIMUMAB		
Yervoy		
Purified		
Monoclonal Antibody		
AbD34294		
HuCAL Fab monovalent		
0.1 mg		

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
ELISA	•			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

Product Form

A monovalent human recombinant Fab (lambda light chain) selected from the HuCAL phage display library, expressed in *E. coli*. The antibody is tagged with a DYKDDDK tag and a double extended Strep-tag (SAWSHPQFEKGGGSGGSGGSAWSHPQFEK). This antibody is supplied as a liquid.

Preparation	StrepTactin affinity chromatography
Buffer Solution	Phosphate buffered saline
Preservative Stabilisers	0.01% Thiomersal
Approx. Protein Concentrations	Antibody concentration 0.5 mg/ml
Immunogen	Ipilimumab/CTLA-4 complex

Specificity

Human Anti-Ipilimumab Antibody, clone AbD34294 specifically recognizes the monoclonal antibody drug ipilimumab when in complex with its target, CTLA-4 (cytotoxic T-lymphocyte antigen-4). The antibody does not recognize free ipilimumab or unbound recombinant human CTLA-4. It can be used to measure levels of ipilimumab in patient samples.

Clone AbD34294 is a monovalent Fab format antibody that can be used to develop a pharmacokinetic (PK) antigen capture assay to measure free ipilimumab captured via immobilized CTLA-4.

Ipilimumab (Yervoy) is a human IgG1/kappa antibody developed from a transgenic mouse. It has been approved by the FDA for the treatment of metastatic melanoma, renal cell carcinoma, and in combination with nivolumab for the treatment of previously treated microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR) metastatic colorectal cancer. Ipilimumab activates the immune system by targeting CTLA-4, a protein receptor that downregulates the immune system. The action of cytotoxic T lymphocytes (CTLs) to recognize and destroy cancer cells is subject to an inhibitory mechanism that interrupts this destruction. Ipilimumab turns off this inhibitory mechanism and allows CTLs to function.

View a summary of all anti-ipilimumab antibodies

Affinity

The intrinsic affinity of the monovalent form of Human anti Ipilimumab antibody, clone AbD34294 is $K_D = 252$ nM as measured by real time, label free molecular interaction analysis on immobilized CTLA-4/ipilimumab complex.

ELISA

Human anti Ipilimumab (drug/target complex) antibody, clone AbD34294 is recommended for use as the detection reagent in an antigen capture assay to measure free Ipilimumab captured via immobilized CTLA-4.

Protocol: PK antigen capture ELISA to measure bound drug exclusively.

Storage

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

Guarantee

12 months from date of despatch

Acknowledgements

This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See bio-rad.com/en-us/trademarks for details.

Yervoy is a trademark of Bristol-Myers Squibb Company.

Health And Safety Information

Material Safety Datasheet documentation #10094 available at: https://www.bio-rad-antibodies.com/SDS/HCA331

	10094
Licensed Use	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
Regulatory	For research purposes only
Technical Advice	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <u>HuCAL Antibodies Technical Manual</u> .

Related Products

Recommended Secondary Antibodies

Rat Anti Synthetic Peptide DYKDDDDK TAG (MCA4764...) HRP

Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A)

LYNX RAPID HRP ANTIBODY CONJUGATION KIT (LNK002P)

HUMAN ANTI IPILIMUMAB (HCA327)

HUMAN ANTI IPILIMUMAB (HCA328)

HUMAN ANTI IPILIMUMAB (HCA329)

HUMAN ANTI IPILIMUMAB (HCA330)

 North & South
 Tel: +1 800 265 7376
 Worldwide
 Tel: +44 (0)1865 852 700
 Europe
 Tel: +49 (0) 89 8090 95 21

 America
 Fax: +1 919 878 3751
 Fax: +44 (0)1865 852 739
 Fax: +49 (0) 89 8090 95 50

To find a batch/lot specific datasheet for this product, please use our online search tool at: bio-rad-antibodies.com/datasheets 'M407692:221008'

Printed on 03 May 2024

© 2024 Bio-Rad Laboratories Inc | Legal | Imprint